47 results
424B3
NTBL
Notable Labs Ltd
5 Sep 23
Prospectus supplement
6:02pm
and effectiveness of a product candidate. Recruitment in rare diseases may be challenging and require the performance of trials in a significant number of sites … , and disrupt any planned or ongoing clinical trials for any number of reasons. Any future pandemics could similarly impact patient recruitment or retention
CORRESP
drztp3vf
26 Jul 23
Correspondence with SEC
12:00am
UPLOAD
16dmd 731sv
19 Jul 23
Letter from SEC
12:00am
S-4/A
sxyjxa7 q28d7uo
30 Jun 23
Registration of securities issued in business combination transactions (amended)
4:38pm
S-4
g0ylz 1jncgd5b
11 May 23
Registration of securities issued in business combination transactions
9:09am
6-K
EX-99.3
78wp8nbbyv7o1gnn7dy
17 May 22
VBL Therapeutics Reports First Quarter 2022 Financial Results
7:00am
424B5
7gh1d
11 Feb 22
Prospectus supplement for primary offering
5:28pm
6-K
EX-99.3
vxw 83v13
15 Nov 21
VBL Therapeutics Reports Third Quarter 2021 Financial Results
7:00am
6-K
EX-99.1
5lgln otjp
30 Aug 21
Current report (foreign)
7:50am
6-K
ogeoa8ukluf5jo xxx55
15 Jun 21
VBL Therapeutics Provides Update on OVAL, a Phase 3 Registration Enabling Study of VB-111 in Ovarian Cancer
7:51am
6-K
EX-99.1
1ooeqxwiwxbud
15 Jun 21
VBL Therapeutics Provides Update on OVAL, a Phase 3 Registration Enabling Study of VB-111 in Ovarian Cancer
7:51am
POS AM
kc97k iloiu09q5
19 Apr 21
Prospectus update (post-effective amendment)
5:17pm
424B8
lzkrnf
19 Apr 21
Prospectus unintentially filed late
5:06pm
424B5
emix6l3st
12 Apr 21
Prospectus supplement for primary offering
9:07am